Florida, USA Patient Shares Lu-177 PSMA Experience in Berlin

Daniel P. is 77 and lives in Florida. A few years ago, he heard the words no one wants to hear - prostate cancer. At first, the path looked clear. Treat the prostate. Remove what you can. Control what you can. Then the disease kept moving.

Over time, Daniel’s cancer showed it was advanced. It had spread to the bones. His PSA kept rising. That number can feel like a scoreboard you never asked to play on. Even when you try one more option, you still watch and wait.

Daniel did not come to this journey unprepared. He had already been through major steps. He had a robotic prostatectomy. He had radiotherapy to the prostate bed. He also had hormone-based treatment and supportive bone therapy, including medicines like Lynparza and Xgeva. He tried Erleada. The patient even needed palliative radiation to ease symptoms and control spots that were causing trouble. He did what many patients do. He kept going, one decision at a time.

By late 2023, Daniel and his family were looking for something more targeted. Radioligand therapy with Lu-177 PSMA stood out. It is a therapy that seeks out PSMA, a marker often found on prostate cancer cells, and delivers radiation right to those cells. The idea felt precise. Almost like a guided approach instead of a wide sweep. The hard part was access. At that time, this treatment was not available to him in the United States.

That is when Daniel reached out to Airomedical. He did not want random promises. He wanted a real plan with a real medical team. Airomedical helped organize his care in Germany. His treatment was arranged at Helios Hospital Berlin-Buch with Prof. Dr. med. Stefan Dresel and the team.

From late 2023 into late 2024, Daniel traveled to Berlin multiple times. In total, he completed six separate cycles of Lu-177 PSMA therapy. Each visit had its own rhythm. Travel, admission, therapy day, monitoring, and recovery. Then back home, and back to normal life as much as possible. The administered activity varied by cycle, roughly in the range of 6,850 to 7,590 MBq. For Daniel, the numbers mattered less than the goal. Calm the disease down. Reduce the metastatic activity. Buy time with quality.

What stayed with him was how structured the process felt. He knew where to go. He knew who was responsible. He knew what the next step was. When you live with metastatic cancer, that kind of clarity can feel like relief.

After the treatment course, Prof. Dresel shared an assessment that gave Daniel something he had not felt in a while. Real momentum. He noted a marked reduction in lesion uptake. Some lesions had totally disappeared. Others showed only faint PSMA uptake. The overall response was described as very good. The plan was simple and careful. Keep monitoring PSA. Do a PSMA PET/CT follow-up in about 6 to 9 months.

For Daniel, the biggest change was not a single scan result. It was the return of stability. After months of travel and treatment, he reached a stable remission. He could breathe again. Not because everything was “over,” but because the disease was no longer racing ahead.

When Daniel looks back, he does not describe the year as easy. He describes it as worth it. He remembers six trips to Berlin, and the strange mix of fatigue and hope that comes with each cycle. He also remembers that the right option can exist, even when it is not close to home. And sometimes, getting to it is the bravest part of the story.